OGN News and Press, Organon & Co. From 02/28/23

Sydney, Australia (ABN Newswire) - Moneghetti Minerals Limited (Moneghetti, the Company) today announced it has identified new high-priority drill targets at the Company's flagship Ecru Gold Project (Ecru) located in the well endowed Cortez District, Nevada USA. The Ecru Project is a Carlin-t...

Ahead of International Women's Day, Organon Canada Spotlights the Importance of Supporting Women's Equity While Highlighting the Cost of Not Investing in Their Health Canada NewsWire 170 employees across Canada will receive paid time off and join 10,000 Organon employees w...

Summary Merck has seen a significant valuation re-rating take place over the past years. This comes amidst the success of Keytruda, which creates some dependency risks as well. With no growth seen in 2023, amidst tough comparables from a pandemic-related contribution in 2022, I am a...

Shares of Organon (NYSE: OGN) fell 15% on Thursday. The pharmaceutical company, which focuses on women's health therapies, established medicines, and biosimilars, reported fourth-quarter and full-year numbers that came in below analysts' consensus expectations. The stock ended the session...

Organon & Co (OGN) Q4 2022 Earnings Conference Call February 16, 2023, 08:30 ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO & Director Matthew Walsh - EVP & CFO Conference Call Participants Terence Flynn - Morgan Stanley U...

Organon ( NYSE: OGN ) stock fell ~4% premarket on Thursday after Q4 results missed estimates. Q4 adjusted EPS declined -28.3% Y/Y to $0.81. Revenue fell -7.4% Y/Y to ~$1.49B but grew +1% Y/Y excluding the impact of foreign currency (ex-FX). "Since these products have been ...

Organon press release ( NYSE: OGN ): Q4 Non-GAAP EPS of $0.81 misses by $0.10 . Revenue of $1.49B (-6.9% Y/Y) misses by $10M . Shares -1.2% PM. Full year 2023 financial guidance provided; full year revenue range of $6.150 billion to $6.450 billion vs. $6.3...

Full year 2022 revenues of $6.2 billion; all three franchises contribute to growth on constant currency basis Full year 2022 diluted earnings per share from continuing operations of $3.59 and non-GAAP Adjusted diluted earnings per share from continuing operations of $5.03 Full year 2022 A...

Summary It’s among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie. Several drugmakers are expected to begin offering biosimilar ver...

Organon ( NYSE: OGN ) is scheduled to announce Q4 earnings results on Thursday, February 16th, before market open. The consensus EPS Estimate is $0.91 (-33.6% Y/Y) and the consensus Revenue Estimate is $1.5B (-6.3% Y/Y). Over the last 1 year, OGN has beaten EPS estimates 1...